For example, in this study we observed changes in PPAR expression between Alport and control podocytes, which has been thoroughly investigated in other kidney disease models (Kiss-Tóth and Roszer, 2008) and has been pharmacologically targeted with promising results (Yang et al., 2006) (reviewed in Romero-Guevara et al., 2020). The gene discussed is PPARA; the disease is kidney disorder.